NEW YORK – OncoDNA announced Thursday that it is partnering with Sophia Genetics to improve analysis and interpretation of genomic profiles.
Gosselies, Belgium-based OncoDNA said that it will customize its OncoKDM genomic interpretation platform to work with Sophia's DDM genomic analytics technology. This, according to the companies, will automate analysis and translation of complex genomic data generated by DDM into actionable recommendations for individual tumor profiles.
"By collaborating with [Sophia], we will be able to leverage our combined scientific and technical knowledge in oncology to provide an even more comprehensive solution that will enable laboratories to integrate large-panel genomic profiling into their workflows and outsmart the molecular complexity of cancer independently," Jean-Pol Detiffe, OncoDNA's chief strategy and innovation officer, said in a statement.
"Combining OncoKDM with our intuitive Sophia DDM platform will further increase options for the interpretation of complex, high-volume genomic data to our global community and beyond," said Lara Hashimoto, chief business officer of Swiss-American firm Sophia. "This partnership will allow us to continue to deliver on the promise and push the boundaries of precision medicine, ultimately benefiting even more patients worldwide."
The firms named Lorraine Institute of Oncology in Nancy, France, as an early user of the combined technology.
"The addition of OncoKDM will further advance our capabilities and help us keep track of the latest cancer treatment options," said Alexandre Harlé, a professor at the French institute. "It will facilitate our routine work, enabling us to analyze an ever-growing panel of cancer-related genes rapidly, identify biomarker-associated drugs or clinical trials for more patients, and discuss complex cases through virtual meetings and tumor boards."